Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
NCT ID: NCT00036218
Last Updated: 2006-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
600 participants
INTERVENTIONAL
2001-12-31
2003-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sumanirole
ropinirole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Modified Hoehn and Yahr Scale Stages 1 through 3.
Age greater than or equal to 30 years old.
Men or women (women of childbearing potential must have a negative pregnancy test at screen) and both must use adequate contraceptive methods.
Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria
Levodopa received for 1-year accumulated interval in the last two years.
Dopamine agonist medications or catechol-o-methyl transferase inhibitors in the 30 days prior to baseline.
Unstable dose regimes of hypnotics, anxiolytics or antidepressants
Dementia
History of stereotaxic brain surgery, psychosis or active epilepsy within past year.
Participation in clinical trial within the previous 30 days.
Malignant melanoma or history of melanoma
Significant medical or pshychiatric condition.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Hot Springs, Arkansas, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Carmichael, California, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Irvine, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
Loma Linda, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Oceanside, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
San Luis Obiapo, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Fairfield, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
Wilmington, Delaware, United States
Pfizer Investigational Site
Boca Raton, Florida, United States
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Fort Lauderdale, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Maitland, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Naples, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Palm Beach Gardens, Florida, United States
Pfizer Investigational Site
Plantation, Florida, United States
Pfizer Investigational Site
St. Petersburg, Florida, United States
Pfizer Investigational Site
Tallahassee, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Conyers, Georgia, United States
Pfizer Investigational Site
Decatur, Georgia, United States
Pfizer Investigational Site
Savannah, Georgia, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Glenbrook, Illinois, United States
Pfizer Investigational Site
Kansas City, Kansas, United States
Pfizer Investigational Site
Lake Charles, Louisiana, United States
Pfizer Investigational Site
Shreveport, Louisiana, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Columbia, Maryland, United States
Pfizer Investigational Site
Frederick, Maryland, United States
Pfizer Investigational Site
Rockville, Maryland, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Ann Arbor, Michigan, United States
Pfizer Investigational Site
East Lansing, Michigan, United States
Pfizer Investigational Site
Grand Rapids, Michigan, United States
Pfizer Investigational Site
Southfield, Michigan, United States
Pfizer Investigational Site
Traverse City, Michigan, United States
Pfizer Investigational Site
Golden Valley, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Saint Cloud, Minnesota, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
Springfield, Missouri, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Henderson, Nevada, United States
Pfizer Investigational Site
Lebanon, New Hampshire, United States
Pfizer Investigational Site
Morristown, New Jersey, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
Ridgewood, New Jersey, United States
Pfizer Investigational Site
Manhasset, New York, United States
Pfizer Investigational Site
Mineola, New York, United States
Pfizer Investigational Site
Mount Vernon, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Asheville, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Norristown, Pennsylvania, United States
Pfizer Investigational Site
Sellersville, Pennsylvania, United States
Pfizer Investigational Site
Upland, Pennsylvania, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Burlington, Vermont, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Bellevue, Washington, United States
Pfizer Investigational Site
Spokane, Washington, United States
Pfizer Investigational Site
Wenatchee, Washington, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Buenos Aires, Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, Buenos Aires, Argentina
Pfizer Investigational Site
Mar del Plata, Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, Buenos Aires F.D., Argentina
Pfizer Investigational Site
Buenos Aires, Buenos Aires F.D., Argentina
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Carolina, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
666E-CNS-0075-021
Identifier Type: -
Identifier Source: org_study_id